Summit Therapeutics SMMT Stock Issuance Proceeds
Stock Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Summit Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions.
The official record: Summit Therapeutics’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's stock issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's stock issuance proceeds?
- Summit Therapeutics (SMMT) reported stock issuance proceeds of $3.8M in Q1 2026.
- How has Summit Therapeutics's stock issuance proceeds changed year-over-year?
- Summit Therapeutics's stock issuance proceeds increased by 88.1% year-over-year, from $2.02M to $3.8M.
- What is the long-term trend for Summit Therapeutics's stock issuance proceeds?
- Over 2 years (2022 to 2025), Summit Therapeutics's stock issuance proceeds has grown at a -76.2% compound annual growth rate (CAGR), from $100M to $5.65M.
- What does stock issuance proceeds mean?
- Total cash raised from selling company stock to investors or employees.
- How do you interpret stock issuance proceeds?
- Higher proceeds indicate strong access to capital markets, though it also signals potential equity dilution for existing shareholders.
- How does stock issuance proceeds compare across companies?
- Standard metric for all public companies; critical for biotechs to monitor as a primary funding source.